Eran Segal

Eran Segal at the Weizmann Institute applies machine learning and computational approaches to decipher relationships between gut microbiome composition and health outcomes including cancer. He has studied Akkermansia muciniphila as a specific microbial species associated with beneficial immunotherapy responses and metabolic health. His computational microbiome profiling tools have broad applications in oncology biomarker discovery.